- Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme2020 | Farmaceutická fakulta v Hradci Králové
- Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme2020 | Farmaceutická fakulta v Hradci Králové
- Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo2023 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Advanced technological tools to study multidrug resistance in cancer2020 | Lékařská fakulta v Plzni
- Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Significance of P-glycoprotein expression in childhood malignant tumors2001 | 2. lékařská fakulta
- Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes2019 | Farmaceutická fakulta v Hradci Králové